

**SUPPLEMENTARY INFORMATION:** When submitting comments or requesting information, please include the information request collection title for reference, in compliance with Section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995.

*Information Collection Request Title:* Poison Help General Population Survey OMB Number 0915-0343, Reinstatement.

*Abstract:* HRSA is requesting approval by OMB for reinstatement with change of a previously approved collection of information (OMB control number 0915-0343). Annually, poison control centers (PCCs) in the U.S. manage approximately 2.8 million calls, providing ready and direct access to vital public health emergency information and response. In 2001, the Poison Help line, a single, national toll-free phone number (800-222-1222) was established to ensure universal access to PCC services, 24 hours a day, 7 days a week. The Poison Help campaign is the only national media effort to promote

awareness and use of the national toll-free phone number.

The Poison Help campaign aims to reach a wide audience, as individuals of all ages are at risk for poisoning and may need to access PCC services. The “Poison Help General Population Survey” is a 10-minute telephone survey designed to assess the campaign’s impact among 2,000 households in the United States. The survey is conducted with an adult household member and addresses topics related to the types of individuals or organizations to contact for information, advice, and treatment related to a poisoning.

*Need and Proposed Use of the Information:* Survey results will be used to guide future communication, education, and outreach efforts and will allow the tracking of longitudinal data from near-identical prior surveys conducted in 2008 and 2011. The survey has been updated to include questions regarding one of the Secretary of HHS’ priority areas, addressing the

opioid crisis, and to definitively ascertain respondents’ knowledge of the Poison Help Line and phone usage.

*Likely Respondents:* This study includes two respondent groups, individuals and households with an adult member 18 years and older.

*Burden Statement:* Burden in this context means the time expended by persons to generate, maintain, retain, disclose, or provide the information requested. This includes the time needed to review instructions; to develop, acquire, install and utilize technology and systems for the purpose of collecting, validating and verifying information, processing and maintaining information, and disclosing and providing information; to train personnel and to be able to respond to a collection of information; to search data sources; to complete and review the collection of information; and to transmit or otherwise disclose the information. The total annual burden hours estimated for this ICR are summarized in the table below.

TOTAL ESTIMATED ANNUALIZED BURDEN—HOURS

Instrument	Number of respondents	Responses per respondent	Total responses	Hours per response	Total burden hours
Survey Respondents .....	2000	1	2000	.166	332
Screened households .....	2600	1	2600	.016	41.6
Total .....	4600	.....	4600	.....	374

Amy McNulty,

Acting Director, Division of the Executive Secretariat.

[FR Doc. 2017-19608 Filed 9-14-17; 8:45 am]

BILLING CODE 4165-15-P

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**National Institutes of Health**

**Government-Owned Inventions; Availability for Licensing**

**AGENCY:** National Institutes of Health, HHS.

**ACTION:** Notice.

**SUMMARY:** Government owned intellectual property covering imaging agents with improved renal clearance available for licensing and commercialization.

**FOR FURTHER INFORMATION CONTACT:**


Licensing information and copies of the patent applications listed below may be obtained by emailing the indicated licensing contact at the National Heart, Lung, and Blood, Office of Technology Transfer and Development Office of Technology Transfer, 31 Center Drive, Room 4A29, MSC2479, Bethesda, MD 20892-2479; telephone: 301-402-5579. A signed Confidential Disclosure Agreement may be required to receive copies of the patent applications.

**SUPPLEMENTARY INFORMATION:** The inventions listed below are owned by an agency of the U.S. Government and are available for licensing in the U.S. in accordance with 35 U.S.C. 209 and 37 CFR part 404 to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent

applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing. A description of the technology available for licensing follows.

**Methods of Using Inhibitors To Enhance Therapeutic Uses of Endocannabinoids**

*Description of Technology:* The invention pertains to methods of using compounds that inhibit fatty acid amide hydrolase (FAAH) enzymes that are responsible for the degradation of oleamide and anandamide. Inhibition of degradation can be used as treatment modality for hypertension and for sleep disorders. The issued patent lists potentially useful compounds, one such useful compound in particular is



**Potential Commercial Applications:**

- Therapeutics for hypertension
- Therapeutics for anxiety disorders
- Therapeutics for sleep disorders

**Development Stage:**

- In vivo data available

**Inventors:** George Kunos and

Alexandros Makriyannis (both of NIAAA)

**Intellectual Property:** HHS Reference

No. E-211-2006/0-US-06.

- U.S. Patent 8,293,724 filed April 6, 2010, issued October 23, 2012.

**Licensing Contact:** Michael

Shmilovich, Esq. CLP; 301-435-5019; [shmilovm@nih.gov](mailto:shmilovm@nih.gov).

**Collaborative Research Opportunity:**

The National Institute of Environmental Health Sciences seeks statements of capability or interest from parties interested in collaborative research to further develop and evaluate, please contact Peg Koelble, Office of Technology Transfer, National Heart, Lung and Blood Institute, [koelblep@nhlbi.nih.gov](mailto:koelblep@nhlbi.nih.gov), 301-594-4095.

Dated: September 7, 2017.

**Michael Shmilovich,**

Senior Licensing and Patenting Manager, National Heart, Lung, and Blood Institute, Office of Technology Transfer and Development.

[FR Doc. 2017-19590 Filed 9-14-17; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### Government-Owned Inventions; Availability for Licensing

**AGENCY:** National Institutes of Health, HHS.

**ACTION:** Notice.

**SUMMARY:** The inventions listed below are owned by an agency of the U.S. Government and are available for licensing to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.

**FOR FURTHER INFORMATION CONTACT:** Chris Kornak, 240-627-3705, [chris.kornak@nih.gov](mailto:chris.kornak@nih.gov). Licensing information and copies of the U.S. patent applications listed below may be obtained by communicating with the indicated licensing contact at the Technology Transfer and Intellectual Property Office (TTIPO), 5601 Fishers Lane, Suite 6D, MSC 9804, Rockville,

MD 20892, tel: 301-496-2644, fax: 240-627-3117. A signed Confidential Disclosure Agreement will be required to receive copies of unpublished patent applications.

**SUPPLEMENTARY INFORMATION:**

Technology description follows.

#### Recombinant HIV-1 Envelope Proteins and Their Use

**Description of Technology:** Millions of people are infected with HIV-1 worldwide. In the U.S., there are about 30,000 new cases of HIV infection reported annually. Currently, there are effective, anti-retroviral therapeutics available to treat or prevent HIV infection. However, available anti-retroviral therapeutics require life-long administration.

During infection, proteases of the host cell cleave gp160 into gp120 and gp41. Gp41 is an integral membrane protein, while gp120 protrudes from the mature virus. Together gp120 and gp41 aggregate as trimers that make up the HIV-1 envelope ("Env") spike, which is a target for neutralizing antibodies.

NIAID researchers have constructed a recombinant HIV-1 trimer immunogen. In particular, the recombinant gp120 protein in the trimer is stabilized in a closed conformation, preventing it from binding to CD4. The advantage of the closed conformation is that it can stabilize the epitopes that bind to broadly neutralizing antibodies, minimize the binding of gp120 with weakly or non-neutralizing antibodies, and prevent conformational changes induced by CD4 as well as immunogen sequestration by CD4 *in vivo*. Research has also indicated that recombinant Env ectodomain trimers can induce higher neutralizing antibody titers than wild type Env trimers in animal models.

This technology is available for licensing for commercial development in accordance with 35 U.S.C. 209 and 37 CFR part 404, as well as for further development and evaluation under a research collaboration.

**Potential Commercial Applications:**

- HIV-1 immunogen
- New methods for isolating broadly neutralizing antibodies

**Competitive Advantages:**

- A new strategy in inducing immune response against HIV-1

**Development Stage:**

- Pre-Clinical; Proof-of-concept studies in nonhuman primate models

**Inventors:**

Paolo Lusso, NIAID, NIH  
Peng Zhang, NIAID, NIH

**Publications:** Pending.

**Intellectual Property:** HHS Reference No. E-102-2016/0—PCT Application

No. PCT/US2017/021573 filed on 03/09/2017.

**Licensing Contact:** Chris Kornak, 240-627-3705, [chris.kornak@nih.gov](mailto:chris.kornak@nih.gov).

**Collaborative Research Opportunity:**

The Technology Transfer and Intellectual Property Office (TTIPO) is seeking parties interested in collaborative research to further develop the technology. In particular, NIAID is interested in partnerships utilizing vector vaccine platforms for expressing these immunogens.

However, NIAID is willing to discuss other applications of this technology. For collaboration opportunities, please contact Chris Kornak, 240-627-3705, [chris.kornak@nih.gov](mailto:chris.kornak@nih.gov).

Dated: September 7, 2017.

**Suzanne Frisbie,**

Deputy Director, Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases.

[FR Doc. 2017-19591 Filed 9-14-17; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Institute on Deafness and Other Communication Disorders; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

**Name of Committee:** National Institute on Deafness and Other Communication Disorders Special Emphasis Panel; Chemical Senses Fellowship Review.

**Date:** October 11, 2017.

**Time:** 12:30 p.m. to 3:00 p.m.

**Agenda:** To review and evaluate grant applications.

**Place:** National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard, Rockville, MD 20852 (Telephone Conference Call).

**Contact Person:** Sheo Singh, Ph.D., Scientific Review Officer, Scientific Review Branch, Division of Extramural Activities, 6001 Executive Blvd., Room 8351, Bethesda, MD 20892, 301-496-8683, [singhs@nidcd.nih.gov](mailto:singhs@nidcd.nih.gov).